SCHEMBL24779593

SCHEMBL24779593

Cc1cccc(COC(=O)NCCCCCCN2C[C@H](O)C[C@H]2CO)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
HSP90AA1 P07900 1/20 0.39
STING1 Q86WV6 1/20 0.39
TGM2 P21980 1/20 0.39
GBA1 P04062 1/20 0.38
UGCG Q16739 1/20 0.38
GBA2 Q9HCG7 1/20 0.38
HTT P42858 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
FOLH1 Q04609 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ABCB1 P08183 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP12 P39900 1/20 0.36
CACNA1G O43497 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20494122 0.88 TGM2 (0.50) KEAP1NFE2L2TGM2HTTDPP8
SCHEMBL13032633 0.88 TGM2 (0.50) KEAP1NFE2L2TGM2HTTDPP8
SCHEMBL13032646 0.77 TGM2 (0.51) KEAP1NFE2L2TGM2HTTDPP8
SCHEMBL3426821 0.73 PREP (0.54) KEAP1NFE2L2TGM2HTTDPP8
SCHEMBL13032648 0.73 PREP (0.54) KEAP1NFE2L2TGM2HTTDPP8
SCHEMBL16281706 0.73 PREP (0.54) KEAP1NFE2L2TGM2HTTDPP8
SCHEMBL18349643 0.71 HTT (0.47) KEAP1NFE2L2TGM2HTTDPP8
SCHEMBL15601764 0.71 HSP90AA1 (0.49) KEAP1NFE2L2HSP90AA1TGM2HTT
SCHEMBL23157239 0.70 DPP8 (0.55) HSP90AA1HTTDPP8DPP7FOLH1
SCHEMBL15601802 0.69 SLC1A3 (0.55) HSP90AA1TGM2HTTDPP8DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220403377-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. 2022-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220403377-A1 MODIFIED iRNA AGENTS NCL, HNRNPA0, HNRNPA1 KEAP1 1695/4885NFE2L2 2294/4885HSP90AA1 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.